ABEONA THERAPEUTICS INC. (NASDAQ:ABEO) Files An 8-K Results of Operations and Financial Condition
Item 2.02.Results of Operations and Financial Condition.
On March 31, 2017, Abeona Therapeutics Inc. issued a press
release regarding its results of operations and financial
condition for the quarter and year ended December 31, 2016. The
full text of the press release is filed as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated herein.
The information in Item2.02 of this Current Report on Form8-K and
Exhibit99.1 attached hereto shall not be deemed filed for
purposes of Section18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by
specific reference in such a filing.
Item 9.01Financial Statements and
Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 |
Press release dated March 31, 2017, entitled Abeona Therapeutics Inc. Reports Q4 2016 Financial Results and Business Highlights |
|
About ABEONA THERAPEUTICS INC. (NASDAQ:ABEO)
Abeona Therapeutics, Inc. (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. The Company is also developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD), and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a clustered, regularly interspaced short palindromic repeats (CRISPR)/Cas9-based gene editing approach to gene therapy program for rare blood diseases. It is developing rare plasma protein therapies, including PTB-101 SDF Alpha (alpha-1 protease inhibitor) for inherited chronic obstructive pulmonary disease. Its product pipeline also consists of MuGard and ProdiGard. ABEONA THERAPEUTICS INC. (NASDAQ:ABEO) Recent Trading Information
ABEONA THERAPEUTICS INC. (NASDAQ:ABEO) closed its last trading session down -0.22 at 4.78 with 258,690 shares trading hands.
